Literature DB >> 11812104

Hypersensitivity reactions to carboplatin.

Maurie Markman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11812104     DOI： 10.1006/gyno.2001.6513

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  7 in total

1.  Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin.

Authors:  Nonna V Kolomeyevskaya; Shashikant B Lele; Austin Miller; Grazyna C Riebandt; Bonnie L Blum; Kunle O Odunsi; Peter J Frederick
Journal:  Int J Gynecol Cancer       Date:  2015-01       Impact factor: 3.437

2.  Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions.

Authors:  Yuki Kawarada; Masayuki Miyazaki; Ayaka Itoh; Risa Araki; Hidetaka Iwamizu; Tomomi Kataoka; Yasuo Kumakura; Akiko Ota; Taku Nagai; Kiyofumi Yamada
Journal:  Int J Clin Oncol       Date:  2017-01-25       Impact factor: 3.402

3.  Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review.

Authors:  Nektaria Makrilia; Ekaterini Syrigou; Ioannis Kaklamanos; Leonidas Manolopoulos; Muhammad Wasif Saif
Journal:  Met Based Drugs       Date:  2010-09-20

4.  The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.

Authors:  Roisin O'Cearbhaill; Qin Zhou; Alexia Iasonos; Martee L Hensley; William P Tew; Carol Aghajanian; David R Spriggs; Stuart M Lichtman; Paul J Sabbatini
Journal:  Gynecol Oncol       Date:  2009-11-27       Impact factor: 5.482

5.  Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin.

Authors:  Shinichi Tate; Kyoko Nishikimi; Ayumu Matsuoka; Satoyo Otsuka; Makio Shozu
Journal:  Cancers (Basel)       Date:  2021-02-05       Impact factor: 6.639

6.  The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer.

Authors:  Alessandra Vultaggio; Maria Cristina Petrella; Federica Tomao; Francesca Nencini; Valentina Mecheri; Andrea Marini; Margherita Perlato; Emanuele Vivarelli; Claudia De Angelis; Ilaria Ferrarini; Serena Pillozzi; Andrea Matucci; Lorenzo Antonuzzo
Journal:  Gynecol Oncol Rep       Date:  2021-10-12

Review 7.  Carboplatin hypersensitivity in relapsed ovarian carcinoma: A therapeutic challenge.

Authors:  Avinash Pandey; Bharat Bhosale; Vimal Pandita; Ashish Singh; Joydeep Ghosh; Jaya Ghosh; Jyoti Bajpai
Journal:  Indian J Med Paediatr Oncol       Date:  2014-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.